PHENPath.com is highlighted by Amgen.com in their recently published article, “Building Towards Patient-Centered Clinical Pathways”

by PHENPath.com | May 24, 2021 | Company News

Tags: Amgen | Clinical Pathways Initiative | Digital Treatment Tool | Empowering Prostate Cancer Patients

— PHENPath.com helps Prostate Cancer patients understand their treatment pathways and treatment options. Prostate Cancer diagnosis, Treatment Options, PSA Recurrence after Radical Prostatectomy, Progression After Radiation, Hormone Sensitive Cancer, Castration Resistent Cancer, Low Risk, Very Low Risk, Intermediate Risk, High Risk, Very High Risk, Metastatic, Regional, Prostate Cancer Diagnosis, Testing, Treatment Therapies, Understanding your Risk Level

PHENPath-Article-Image

PHEN is a partner organization of the Amgen Clinical Pathways initiative, PHENPath.com helps empower prostate cancer patients through its first digital treatment pathway tool of its kind.

We encourage you to read the article by clicking the button link below

Read the Article

Follow Us

Categories

← Prev: PHENPath.com provides helpful information about your Initial Prostate Cancer Diagnosis. We invite you to learn more if you are a patient diagnosed with prostate cancer prior to any treatment. Next: PHENPath.com supports patients in making informed and shared-decisions with their doctors about their Prostate Cancer treatment – Resources that will help you along your journey. →

©2020-2024 Prostate Health Education Network, Inc. All Rights Reserved.

Supported by: Amgen logo

Patient Treatment Education and Empowerment Initiative (PTEE) Sponsors: AMGEN | Bayer | Janssen Oncology | Merck | Sumitomo Pharma | Pfizer | Lantheus

Pin It on Pinterest